Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy
A. H. Kadam, K. Kandasamy, T. Buss, B. Cederstrom, C. Yang, S. Narayanapillai, J. Rodriguez, M. D. Levin, J. Koziol, B. Olenyuk, Z. Borok, A. Chrastina, J. E. Schnitzer
This paper develops a bispecific antibody that targets caveolae to deliver TGF-β inhibitors specifically to lungs, achieving ultra-low dose therapeutic efficacy in a rat model.
bioRxiv · Sep 12, 2022Bioengineering